Drugs / IACS-010759
IACS-010759
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03291938 | Nov 2017 → Nov 2020 | lymphoma, metastatic malignant neoplasm, pancreatic ductal adenocarcinoma, triple-negative breast carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02882321 | Sep 2016 → Apr 2022 | acute myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IACS-010759 | “IACS-010759” NCT03291938 ↗ |
| Known as | IACS-10759 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650499 ↗ |
| Known as | Oxidative phosphorylation inhibitor iacs-010759 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650499 ↗ |
| Known as | OXPHOS Inhibitor IACS-010759 | “OXPHOS Inhibitor IACS-010759” NCT03291938 ↗ |
| Action | Inhibit | “complex I inhibitor” PMID 36658425 ↗ Jan 2023 |
| Modality | Small molecule | “small-molecule complex I inhibitor” PMID 36658425 ↗ Jan 2023 |
| Route | Oral | “orally (PO)” NCT02882321 ↗ |